Table 2.
PRO measures in the ITT patient group (paired samples)
| 16 weeks | 8 months | 12 months | |
|---|---|---|---|
| ACT score | n=222 | n=177 | n=187 |
| Mean (SD) at baseline | 9.76 (4.29) | 9.77 (4.38) | 9.84 (4.34) |
| Mean (SD) at visit | 15.01 (5.71) | 14.99 (5.78) | 14.41 (5.69) |
| Mean difference (95% CI) | 5.26 (4.58 to 5.93)* | 5.22 (4.43 to 6.00)* | 4.57 (3.75 to 5.38)* |
| AQLQ score | n=192 | n=149 | n=161 |
| Mean (SD) at baseline | 3.27 (1.29) | 3.14 (1.28) | 3.20 (1.27) |
| Mean (SD) at visit | 4.65 (1.55) | 4.61 (1.54) | 4.39 (1.48) |
| Mean difference (95% CI) | 1.38 (1.18 to 1.58)* | 1.47 (1.25 to 1.70)* | 1.20 (0.97 to 1.42)* |
| EQ-5D index | n=215 | n=167 | n=173 |
| Mean (SD) at baseline | 0.59 (0.25) | 0.58 (0.26) | 0.58 (0.25) |
| Mean (SD) at visit | 0.71 (0.25) | 0.68 (0.26) | 0.69 (0.26) |
| Mean difference (95% CI) | 0.12 (0.09 to 0.15)* | 0.10 (0.06 to 0.13)* | 0.11 (0.08 to 0.15)* |
| EQ-5D VAS | n=196 | n=162 | n=166 |
| Mean (SD) at baseline | 54.2 (20.3) | 53.5 (20.3) | 54.3 (20.1) |
| Mean (SD) at visit | 66.8 (21.2) | 67.1 (21.9) | 67.1 (20.9) |
| Mean difference (95% CI) | 12.5 (9.5 to 15.5)* | 13.6 (10.3 to 17.0)* | 12.8 (9.4 to 16.2)* |
*p<0.001.
ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; EQ:5D VAS, EuroQol five-dimensions visual analogue scale; ITT, intention to treat; PRO, patient-reported outcome.